In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
1don MSN
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...
The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...
Home-based HIV counseling and relationship building improved HIV testing, diagnoses and viral suppression among pregnant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback